Strategic Planning & Communication Flashcards

A regulatory affairs professional discovers a discrepancy between data in a published clinical study report and the submission dossier. What is the FIRST action to take?

Answer: Investigate the source of the discrepancy, document findings, and notify appropriate internal stakeholders before determining regulatory action

Investigating and documenting the discrepancy before taking action ensures the root cause is understood and the appropriate corrective or reporting strategy is implemented.

In the context of regulatory strategic planning, what does 'regulatory intelligence' refer to?

Answer: Systematic gathering and analysis of information about regulatory environments, agency precedents, and competitive approvals to inform strategy

Regulatory intelligence is the ongoing collection and analysis of external regulatory data—including guidances, approvals, and enforcement trends—to shape submission strategy and anticipate agency expectations.

Which of the following scenarios BEST illustrates an effective use of a pre-submission meeting with FDA?

Answer: Seeking FDA feedback on a proposed clinical trial design and endpoints before initiating the pivotal study

Pre-submission (Pre-Sub) meetings are used to obtain FDA feedback on study designs, endpoints, and data requirements before resource-intensive pivotal studies begin.

A global regulatory team must prioritize which markets to enter first for a new drug. Which combination of factors is MOST relevant to this strategic decision?

Answer: Market size, regulatory timeline, reimbursement environment, and unmet medical need

Market prioritization in regulatory strategy balances commercial opportunity (market size, reimbursement), regulatory feasibility (timeline, pathway), and clinical need.

When a regulatory agency requests labeling negotiations that could significantly restrict the approved indication, which approach MOST effectively protects the sponsor's position?

Answer: Present a counter-proposal supported by robust clinical data analyses and a clear benefit-risk argument

A data-supported counter-proposal demonstrates scientific rigor and provides the agency with evidence-based rationale, giving the strongest basis for negotiating a broader label.

What is the MAIN strategic advantage of obtaining Orphan Drug Designation (ODD) for a product intended for a rare disease?

Answer: Seven years of market exclusivity upon approval, plus development incentives including tax credits and fee waivers

Orphan Drug Designation provides seven years of post-approval market exclusivity and financial incentives such as tax credits on clinical costs and waived user fees.

Which element is MOST important to address in a regulatory communication plan for a product experiencing a post-market safety signal?

Answer: Defining which regulatory authority must be notified, within what timeframe, and with what supporting data

A safety signal communication plan must clearly specify applicable reporting obligations, regulatory timelines, and data requirements for each relevant authority to ensure compliant and timely notification.